Only Zoladex®
goserelin acetate implant

The only ready-to-use, biodegradable GnRH* agonist implant

*A: only

GnRH: gonadotropin-releasing hormone.
Zoladex meets the needs of nurses\textsuperscript{4,5}

The majority of patients reported minimal pain (VAS* <10 mm) from the Zoladex injection\textsuperscript{5}

In a study with patients, there was no significant difference between the pain levels experienced from injections of Zoladex compared to injections of intramuscular leuprolide acetate\textsuperscript{5}

A total of 50 patients were blindfolded and administered either Zoladex or leuprolide acetate into the anterior abdominal wall. Each group (24 Zoladex and 26 leuprolide acetate) received 2 injections 4 weeks apart. Following each injection, patients were asked to record the pain of injection on a visual analogue scale ranging from 0 mm (no discomfort) to 100 mm (maximal discomfort).\textsuperscript{3}

In a study with nurses, it took an average of 1.70 minutes to prepare and deliver Zoladex\textsuperscript{4}

91% agreed that it was easy to prepare Zoladex prior to administration\textsuperscript{4}

85% agreed that there were good safety precautions with Zoladex\textsuperscript{4}

76% agreed that the Zoladex syringe was easy to manipulate\textsuperscript{4}

Zoladex SafeSystem\textsuperscript{®}: The only ready-to-use GnRH agonist\textsuperscript{1,2}

Designed to provide consistent, reliable delivery of Zoladex\textsuperscript{1,2}

Zoladex features:
  • A sterile, siliconized, triple-beveled hypodermic needle with easy-glide SafeSystem
  • No assembly, mixing, or refrigeration required
  • Implant provides consistent, reliable delivery of medication
  • Each syringe is provided with a convenience pack (contains gauze, alcohol wipe, and bandage)
  • Designed with a protective needle sleeve and guard to reduce needlestick injuries\textsuperscript{3} – Zoladex SafeSystem needle is automatically covered upon withdrawal

Actual sizes:
  - 3.6 mg: 1 cm in length
  - 10.8 mg: 1.7 cm in length

Zoladex SafeSystem®
- Biodegradable implant
- Automatic protective needle sleeve
- Needle guard
- Finger grip

Zoladex SafeSystem
- A sterile, siliconized, triple-beveled hypodermic needle with easy-glide SafeSystem
- No assembly, mixing, or refrigeration required
- Implant provides consistent, reliable delivery of medication
- Each syringe is provided with a convenience pack (contains gauze, alcohol wipe, and bandage)
- Designed with a protective needle sleeve and guard to reduce needlestick injuries – Zoladex SafeSystem needle is automatically covered upon withdrawal

Randomized crossover study with 82 nurses timed in the administration (preparation and delivery) of the system used to administer Zoladex and the vial system used to administer leuprolide acetate. Preferences and perceptions of the ease of use and relative safety of the two injection systems were also assessed.\textsuperscript{4}

\*VAS: visual analogue scale.
A visual comparison of selected GnRH agonist delivery systems

ZOLADEX SAFESYSTEM®

**Actual sizes:**
- 3.6 mg: 1 cm in length
- 10.8 mg: 1.7 cm in length

- Finger grip
- Automatic protective needle sleeve
- Needle guard
- Biodegradable implant

Needle is automatically covered upon withdrawal

LUPRON DEPOT®

Prefilled dual-chamber syringe

- Diluent (NOTE: Liquid in first chamber)
- Lyophilized microspheres (NOTE: Powder in second chamber)

- White plunger
- LuproLoc® safety device

Syringe A prefilled with ATRIGEL® polymer system

ELIGARD®

- Syringe A prefilled with ATRIGEL® polymer system
- Syringe B prefilled with leuprolide acetate powder

- Needle
- Needle safety shield

tray 1

- Long white replacement plunger rod

tray 2
Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in patients with a known hypersensitivity to GnRH, GnRH agonist analogues, or any of the components in ZOLADEX. ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormonal changes that occur with ZOLADEX treatment. ZOLADEX should not be given to women with undiagnosed abnormal vaginal bleeding.

Pregnancy must be excluded for use in benign gynecological conditions. Women should be advised against becoming pregnant while taking ZOLADEX. Effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy. Transient worsening of tumor symptoms, or the occurrence of additional signs and symptoms of breast cancer, may occasionally develop during the first few weeks of treatment. Some patients may experience a temporary increase in bone pain. Monitor patients at risk for complications of tumor flare.

Hyperglycemia and an increased risk of developing myocardial infarction, may occasionally develop during the first few weeks of treatment. Data suggest a possibility of partial reversibility. In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients. In women the most frequently reported adverse reactions were related to hypoestrogenism. The adverse reaction profile was similar for women treated for breast cancer, dysfunctional uterine bleeding, and endometriosis.

The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometriosis were hot flashes (96%), vaginitis (75%), headache (75%), decreased libido (61%), emotional lability (60%), depression (54%), sweating (45%), acne (42%), breast atrophy (33%), seborrhea (26%), and peripheral edema (21%).

The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometrial thinning were vasodilation/hot flashes (57%), headache (32%), sweating (16%), and abdominal pain (11%).

Pregnancy must be excluded for use in benign gynecological conditions. Women should be advised against becoming pregnant while taking ZOLADEX. Effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy. Transient worsening of tumor symptoms, or the occurrence of additional signs and symptoms of breast cancer, may occasionally develop during the first few weeks of treatment. Some patients may experience a temporary increase in bone pain. Monitor patients at risk for complications of tumor flare.

Hyperglycemia and an increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in men receiving a GnRH agonist should be monitored for symptoms and signs suggestive of increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in men receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice. Hypercalcaemia has been reported in some prostate and breast cancer patients with bone metastases after starting treatment with ZOLADEX. If hypercalcaemia does occur, appropriate treatment measures should be initiated. Hypersensitivity, antibody formation, and acute anaphylactic reactions have been reported with GnRH agonist analogues. ZOLADEX may cause an increase in cervical resistance. Therefore, caution is recommended when dilating the cervix for endometrial ablation.

Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. Injection site injury and vascular injury including pain, hematoma, hernorrhagia, and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation.

Treatment with ZOLADEX may be associated with a reduction in bone mineral density over the course of treatment. Data suggest a possibility of partial reversibility. In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients. In women the most frequently reported adverse reactions were related to hypoestrogenism. The adverse reaction profile was similar for women treated for breast cancer, dysfunctional uterine bleeding, and endometriosis.

The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometriosis were hot flashes (96%), vaginitis (75%), headache (75%), decreased libido (61%), emotional lability (60%), depression (54%), sweating (45%), acne (42%), breast atrophy (33%), seborrhea (26%), and peripheral edema (21%).

The most commonly reported adverse reactions with ZOLADEX in clinical trials for endometrial thinning were vasodilation/hot flashes (57%), headache (32%), sweating (16%), and abdominal pain (11%).

The most commonly reported adverse reactions with ZOLADEX in breast cancer clinical trials were hot flashes (70%), decreased libido (47.7%), tumor flare (23%), nausea (11%), edema (5%), and malaise/fatigue/lethargy (5%). Injection site reactions were reported in less than 1% of patients. The most commonly observed adverse reactions during ZOLADEX treatment for prostatic carcinoma were due to the expected physiological effects from decreased testosterone levels. The most common adverse reactions (incidence of >5%) in prostate clinical trials were:

- For ZOLADEX 3.6-mg: Hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%)
- For ZOLADEX 10.8-mg: Hot flashes (64%), pain (general) (14%), gynecomastia (8%), pelvic pain (6%), and bone pain (6%)

In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence >5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%). Treatment with ZOLADEX and flutamide did not add substantially to the toxicity of radiation treatment alone.

**Indications**

- Management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate in combination with flutamide. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
- Palliative treatment of advanced carcinoma of the prostate.
- Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months. Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
- Palliative treatment of advanced breast cancer in pre- and perimenopausal women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please see www.Zoladexhcp.com or your local representative for the Full Prescribing Information. Individual patient results may vary.

**References:**

Zoladex administration guide

PREPARATION: No refrigeration or premixing is required with Zoladex—the siliconized hypodermic needle with easy-glide SafeSystem comes ready to administer.

ADMINISTRATION

1. Clean an area of the anterior abdominal wall (below the navel) for injection using an alcohol swab.

2. Inspect the foil pouch and syringe for damage. Remove the syringe from the pouch and hold it at a slight angle to make sure part of the implant is visible. Remove the plastic safety tab and needle cover.

3. Pinch the patient’s skin using aseptic technique at the prepared injection site, and hold the needle with the bevel facing up at an injection angle of 30°-45°.
   
   NOTE: Extra care should be taken with patients with low BMI and/or patients receiving a full dose of anticoagulation.

4. Insert the needle, with the bevel facing up, until the protective sleeve touches the patient’s skin. Take care not to penetrate the muscle or peritoneum.
   
   NOTE: If the needle penetrates a large blood vessel, blood will immediately be seen in the syringe chamber. If this occurs, withdraw the needle and inject a new syringe at a new location. Monitor patients for signs of abdominal hemorrhage.

5. Depress the plunger until you hear a “CLICK.” The click ensures the SafeSystem has been activated and the implant has been deposited in the correct location.

6. Withdraw the needle and allow the protective sleeve to slide and cover the needle; dispose in an approved sharps container.


Additional support services such as reimbursement information, patient support, and in-office injection training are available by calling 1-844-ZOLADEX (1-844-965-2339).

For questions about Zoladex, please contact TerSera Therapeutics, from 8 AM to 6 PM EST, at 1-888-374-6627. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088. This product information is intended for US health care professionals only.

ZOLADEX® and SAFESYSTEM® are registered trademarks of AstraZeneca or its affiliates and are used herein under license. All other trademarks mentioned herein are the property of their respective owners. © 2018 TerSera Therapeutics LLC. All rights reserved. ZOL-P-1068 (04/2018)